🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients With Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.

Recruitingn/aAges 18 Years - anyAllFondazione G.B. Bietti, IRCCS
NCT06227611 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness Exclusion Criteria: * age\<18 years * unable to read, understand and sign the written informed consent * unable to perform visual field test * advanced glaucoma with C/D\>0.7 * other causes of optic neuropathies * retinal or macular diseases * lens or corneal opacities * spherical refractive defect \>± 6D * cylindric refractive defect \>± 3D
💊

What it tests

  • Not listed
📍

Where

2 sites
IRCCS-Fondazione GB Bietti
Rome, Italy
University of Rome Tor Vergata
Rome, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy